Prospective study of fertility‐sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women
Abstract
Objective
To confirm that the efficiency of the use of chlormadinone acetate for 6 months to obtain remission of atypical hyperplasia or endometrial carcinoma is comparable to that of the use of other fertility‐sparing treatments.
Method
The present study is based on the PREFERE prospective registry. All the patients received 3 or 6 months of chlormadinone acetate and were evaluated by hysteroscopic resection and pipelle sampling every 3 months.
Results
Ninety‐four patients were included. Seventy‐nine patients achieved complete remission at 6 months (84%). No patients stopped treatment because of a lack of tolerance. Twenty‐four per cent of the patients achieved a live birth.
Conclusion
Chlormadinone acetate is an effective and well‐tolerated fertility‐sparing treatment. Its benefits over other progestins are its tolerability, and its absence of contraindications, which make it a good choice for patients with thromboembolism and high vascular risk.